Medigen Vaccine Biologics Corporation (TPEX:6547)
Taiwan · Delayed Price · Currency is TWD 45.20
+1.00 (2.26%)
May 29, 2026, 1:30 PM CST
Medigen Vaccine Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -289.01 | -281.71 | -80.47 | -1,160 | -1,475 | 1,410 |
Depreciation & Amortization | 143.89 | 140.46 | 134.99 | 130 | 127.26 | 112.33 |
Other Amortization | 1.33 | 1.33 | 1.45 | 1.17 | 0.63 | 0.22 |
Loss (Gain) From Sale of Assets | 10.28 | 9.2 | -0.41 | - | - | - |
Loss (Gain) From Sale of Investments | -1.35 | - | -1.42 | 9.64 | 16.55 | 0.07 |
Stock-Based Compensation | 39.49 | 31.01 | 14.16 | 18.31 | 75.61 | 68.82 |
Other Operating Activities | 36.13 | -3.34 | 71.32 | -16.66 | 19.32 | -0.02 |
Change in Accounts Receivable | 7.56 | -11.99 | 31.08 | 45.29 | 445.79 | -635.73 |
Change in Inventory | 10.94 | 58.31 | -68.43 | 161.15 | 18.71 | -486.06 |
Change in Accounts Payable | 4.31 | -2.79 | -12.5 | -82.64 | 21.72 | 65.63 |
Change in Unearned Revenue | - | - | - | - | -111.41 | 111.41 |
Change in Other Net Operating Assets | 3.62 | 10.45 | -49.03 | 411.02 | -353.41 | -67.03 |
Operating Cash Flow | -32.81 | -49.09 | 40.75 | -482.56 | -1,214 | 579.89 |
Capital Expenditures | -143.81 | -50.64 | -34.3 | -38.69 | -139.17 | -133.63 |
Sale of Property, Plant & Equipment | 3.29 | 3.29 | 0.87 | - | - | 120 |
Sale (Purchase) of Intangibles | -1.14 | -1.14 | -0.68 | -2.27 | -1.17 | -1.34 |
Investment in Securities | -206.46 | 20 | 1,050 | 636.38 | -2,279 | -881.8 |
Other Investing Activities | -231.7 | -6.81 | 1.29 | 74.4 | 134.74 | -33.93 |
Investing Cash Flow | -579.83 | -35.3 | 1,018 | 669.83 | -2,285 | -930.69 |
Short-Term Debt Issued | - | - | - | - | - | 30 |
Long-Term Debt Issued | - | - | - | - | 1,755 | - |
Total Debt Issued | 787.1 | - | - | - | 1,755 | 30 |
Short-Term Debt Repaid | - | - | - | - | - | -30 |
Long-Term Debt Repaid | - | -39.19 | -1,740 | -11.78 | -11.56 | -1.93 |
Total Debt Repaid | -41.27 | -39.19 | -1,740 | -11.78 | -11.56 | -31.93 |
Net Debt Issued (Repaid) | 745.83 | -39.19 | -1,740 | -11.78 | 1,744 | -1.93 |
Issuance of Common Stock | - | - | 3.47 | 13.37 | 1,579 | 55.68 |
Other Financing Activities | - | - | - | - | - | -2.58 |
Financing Cash Flow | 745.83 | -39.19 | -1,736 | 1.59 | 3,323 | 51.18 |
Foreign Exchange Rate Adjustments | - | - | 0.11 | 0 | 0.35 | -0.11 |
Net Cash Flow | 133.19 | -123.58 | -677.51 | 188.87 | -175.44 | -299.73 |
Free Cash Flow | -176.62 | -99.72 | 6.46 | -521.25 | -1,353 | 446.26 |
Free Cash Flow Margin | -29.26% | -16.26% | 1.07% | -133.78% | -370.64% | 13.60% |
Free Cash Flow Per Share | -0.55 | -0.30 | 0.02 | -1.59 | -4.18 | 1.39 |
Cash Interest Paid | 8.66 | 8.66 | 7.72 | 7.32 | 7.53 | 6.02 |
Levered Free Cash Flow | -119.75 | -3.72 | -81.08 | -164.31 | -744.24 | -288.35 |
Unlevered Free Cash Flow | -113.66 | 1.79 | -69.27 | -140.83 | -727.43 | -284.59 |
Change in Working Capital | 26.43 | 53.98 | -98.88 | 534.82 | 21.39 | -1,012 |